13:HKEXIndustrial and Commercial Bank of China Limited Analysis
Data as of 2026-07-22 - not real-time
HK$6.96
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
ICBC trades at HK$6.96, comfortably above its 20‑day (HK$6.71) and 50‑day (HK$6.82) moving averages, indicating short‑term momentum. The 14‑day RSI sits at 56, suggesting neither overbought nor oversold conditions. MACD shows a bullish crossover (line positive, histogram +0.05) reinforcing upward bias. The stock is priced near the mid‑range of its 52‑week band, with support at HK$6.29 and resistance at HK$7.14. Volatility over the past 30 days is high at ~29%, but beta is very low (≈0.1‑0.36), implying limited market‑wide swings. The technical upside potential of ~19.6% aligns with analyst target median of HK$8.46.
Valuation is compelling: trailing PE of 6 versus industry average of 17.8 and price‑to‑book of 0.54. Dividend yield of 4.99% with a 30% payout ratio points to sustainable cash returns given the HK$4 trillion cash pile. Revenue is growing modestly (3.4% YoY) and profitability remains strong (profit margin 55%). However, operating cash flow is negative, flagging a short‑term cash conversion issue. Regulatory scrutiny in China and the bank’s massive debt load add medium‑level risk, yet the firm’s scale and low beta keep overall risk moderate. The consensus “strong buy” from 16 analysts and a 19% upside estimate support a buying case across horizons.
Valuation is compelling: trailing PE of 6 versus industry average of 17.8 and price‑to‑book of 0.54. Dividend yield of 4.99% with a 30% payout ratio points to sustainable cash returns given the HK$4 trillion cash pile. Revenue is growing modestly (3.4% YoY) and profitability remains strong (profit margin 55%). However, operating cash flow is negative, flagging a short‑term cash conversion issue. Regulatory scrutiny in China and the bank’s massive debt load add medium‑level risk, yet the firm’s scale and low beta keep overall risk moderate. The consensus “strong buy” from 16 analysts and a 19% upside estimate support a buying case across horizons.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 7/10
Key Factors
- Bullish MACD crossover
- Price trading above short‑term moving averages
- High dividend yield of 4.99%
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Significant valuation gap (PE 6 vs industry 17.8)
- Analyst target median price implies ~19% upside
- Sustainable dividend with 30% payout ratio
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Massive cash reserves and low beta provide stability
- Potential regulatory and macro‑economic headwinds
- Consistent dividend policy supporting total return
Key Metrics & Analysis
Financial Health
Revenue Growth3.40%
Profit Margin55.15%
P/E Ratio6.0
ROE8.89%
ROA0.70%
P/B Ratio0.5
Op. Cash FlowHK$-73994002432
Industry P/E17.8
Technical Analysis
TrendNeutral
RSI56.3
SupportHK$6.29
ResistanceHK$7.14
MA 20HK$6.71
MA 50HK$6.82
MA 200HK$6.49
MACDBullish
VolumeDecreasing
Fear & Greed Index90.98
Valuation
Target PriceHK$8.33
Upside/Downside19.62%
GradeUndervalued
TypeValue
Dividend Yield4.99%
Risk Assessment
Beta0.36
Volatility29.22%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.